domingo, 4 de octubre de 2015

Lar-Creel un laboratorio de comedia / "opera soap"

"Pero no me puedo dar el lujo 
de tener sentimientos 
tan vulgares como el miedo, 
porque el miedo sólo paraliza 
y sólo la gente como nosotros 
tiene la sangre fría 
para ganar las batallas del mundo, 
sin perder el tiempo en tonterías". 
Catalina Creel

Los esposos Catalina Creel y Carlos Larios eran dueños del gigantesco consorcio farmacéutico llamado Lar-Creel. Catalina le había hecho creer a todo el mundo que José Carlos, su hijastro, le había arrancado el ojo derecho con un trompo cuando era niño, pero es mentira.

Esto lo hizo para que Carlos tomara preferencia por Alejandro, único hijo de Catalina Creel; asimismo, logró destruir así la autoestima de José Carlos.

"Enredándose" en las RRSS...

sábado, 3 de octubre de 2015

Big Pharma: The game.

What if you had it in your power to rid the world of disease, to improve the lives of millions, to ease suffering and cure the sick… and earn a tidy profit?

As the head of your own Pharmaceutical Conglomerate you have this power resting in your hands. Will you use it for good? Being totally altruistic may not be the best business plan. The uncomfortable truth (is there an ointment for that?) is that some remedies are more profitable than others and illness is good for business.

Welcome to the world of Big Pharma!

The pharma industry divides opinions on its morality, but what has always stood out is the fact that in this business, profit is king.

I do not envy pharma executives – who are answerable to eager shareholders and investors none-too-keen on a disappointing set of financial results – but I am nonetheless curious about their work, the pressures they come under, and the industry’s ethics.

So I see the new strategy game ‘Big Pharma’, from independent computer game developer Twice Circled, as a chance to get a more light-hearted feel for that world. I can learn from the safety of my own home, without having to worry about my job security or any crippling lawsuits that might come my way from poisoning my customers.

For a sense of what the game is all about, think The Sims, but in the pharma world. Your goal is to import compounds, discover their active ingredients, create the right concentrations and mixtures – and then of course sell the optimised pills for maximum profit.
Firing up the colourful game for the first time, you have your hand held nicely through a tutorial that serves as a good introduction to the mechanics of the factory and production line.
Accompanied by some very pleasing animations and sound effects (not to mention an official soundtrack), I was quickly able to arrange the machinery and conveyor belts in the right order to produce my new company’s first drug – I chose a headache cure – and also to name it, which is a fun touch.
Like their real life counterparts, these virtual pills have benefits but also side effects, and the job of the God-like player/pharma executive is to use all of the tools in the company’s arsenal to get the balance just right: maximising the positive effects and minimising the negative.
The gameplay is fairly simple, but rewarding; once you get a feel for creating drugs, it is really a question of upscaling the production and reinvesting the money into larger factories and better technologies to create new and more lucrative cures. It is satisfying to watch your virtual drug empire grow and the profits alongside it, while rival firms look on enviously.
But they will only do so if you get things right. The artificial intelligence pharma companies generated by the computer game are also constantly working on their own competing products to your drug blockbusters. If they do a better job of it, your sales will fall. The fact that you have to constantly adapt to their moves keeps the game challenging and adds incentive to keep playing. (Más)

viernes, 2 de octubre de 2015

Cinema Paradiso: Little Fockers / Ahora los padres son ellos

Greg Focker con diez años de matrimonio encima y ciertos problemas de dinero, tras un fuerte acoso por parte de Andy García (Jessica Alba) representante (Drug ambassador) del laboratorio Boston Pharmaceuticals (ficción), decide incorporarse a trabajar, a escondidas de su familia, como Key Opinion Leader (KOL) de Sustengo.


KOL´s (I) una forma de llamar a los "Líderes de opinión"

Y parece que lo hace bien.
Y el "acoso" de la intensifica.

 Sustengo es otro producto más, remedo de Viagra (Pfizer), indicado en el tratamiento de la “disfunción eréctil”.  Y su consumo por alguno de los protagonistas da lugar a una serie de hilarantes situaciones.

  • Safe for heart patients. 
  • Increased sexual performance. 
  • Improved sexual response.

Es la parte de la "peli" que a nosotros mas nos puede interesar . 

Todo lo demás una serie de gags que continúan la línea de esta “saga” (3ª entrega) de la familia Fockers

Ver también:

Little Fockers Product Placement: Yo, La Sustengo

Cinema Paradiso: Sin límites (Limitless) / Neil Burger

NZT una pí película: Limitless / Sin límites (para el Marketing, al menos)

Go, Team Coco! / Lilly Diabetes & Disney

Lilly Diabetes has expanded its collection of resources for families of children with type 1 diabetes with the publication of Go, Team Coco! The story is the fourth Disney book in a series featuring Coco, a charismatic and fun-loving monkey who has type 1 diabetes. The book will be available immediately from most pediatric endocrinologists' offices in the U.S. 

 "Lilly Diabetes is proud to bring new resources featuring Disney content that has a positive impact on families living with type 1 diabetes," said Mike Mason, vice president U.S., Lilly Diabetes. "Since launching the first book four years ago, these stories have inspired and motivated children and families affected by the disease." 

Go, Team Coco! is three stories in one book. Readers will learn about how Coco and her family cope with her diagnosis at the hospital, the new routines they establish at home, and her first follow-up visit to the doctor. Coco, along with other Disney characters, helps readers understand that with proper planning and management, children with diabetes and their families can still have fun and do things that children without the condition can do. 

Each year, more than 18,000 children in the United States are diagnosed with type 1 diabetes.1 For them and their families, the challenges of living with diabetes can be daunting. Through this collection of Disney stories, Lilly Diabetes sends empowering messages of inspiration, education, and practical advice to families with children who have type 1 diabetes-changing the focus from what they can't do to what they can do. 

Go, Team Coco! is the latest in a series of books for young children in the Lilly Diabetes/Disney collection that also includes Coco and Goofy's Goofy Day, Coco Goes Back to School, and Coco's First Sleepover. A series of chapter books for older children is also available. All the books are available free of charge through pediatric endocrinologists' offices, and most are also accessible digitally at, the Lilly Diabetes/Disney online destination dedicated to type 1 diabetes. 

Select titles have been translated into over 30 languages and are offered in more than 50 countries. (Más)

jueves, 1 de octubre de 2015

The S&P 500® Catholic Values Index Pharma / L@s "excluidos" por..."impios"?

Pecado y virtud conviven en Wall Street. Hay empresas rentables y ruinosas, recién nacidas o consolidadas, las que pagan bien, las que pagan mal y las que hacen ambas cosas al mismo tiempo… Y la mayor parte de ello se puede conocer por la memoria de las empresas que cotizan en Bolsa. Pero ahora, gracias a S&P Dow Jones Indices, supuestamente también se puede identificar a las que son buenas católicas y las que no en base a una serie de criterios muy particulares. La compañía acaba de lanzar el primer índice S&P 500 de Valores Católicos, que ha elaborado a partir del índice general ya existente (el S&P 500), excluyendo a una cincuentena que no cumplen con esos parámetros. (...) 
  ...y firmas farmacéuticas como Pfizer, Johnson&Johnson o Merck tampoco tienen hoy por hoy abierto el paso en el índice de compañías de valores católicos. Sí entran Goldman Sachs, JP Morgan, Ralph Lauren o Procter&Gamble, entre otras.(...) 

Este tipo de índices sirve como herramienta de análisis para la comunidad inversora —a veces se les agrupa por sectores o por otras características— y también como guía de inversiones. El Oblate International Pastoral Investment Trust, con 200 instituciones católicas participantes en todo el mundo, es público objetivo para esta iniciativa. El Padre Séamus Finn, jefe de inversiones, destaca que rentabilidad y ética no son contradictorios, como muestra la buena salud de muchos fondos vinculados al catolicismo.

Firmas rechazadas sin explicaciones

S&P´s excluye de su índice de valores católicos a empresas de los más variados sectores sin dar explicaciones al respecto. Entre los sectores con más empresas consideradas pecadoras está el de la salud, con Aetna, Agilent Technologies, Allergan, Ampherol, Endo, HCA, Humana, Johson&Johnson, McKesson, Merck&Co, Perrigo, Pfizer, Tenet Healthcare,  Utd Health Group y Universal H. Service

(Ver más

Vender OTC "on line" / Carlos González Bosch, Presidente del Grupo Cofares

Carlos González Bosch, Presidente del Grupo Cofares, explica en el siguiente vídeo algunos aspectos relevantes sobre la venta online de medicamentos, que ya está vigente en nuestro país. España es uno de los últimos países que se ha incorporado a esta práctica, cuyos precursores son Alemania (que comenzó a vender medicamentos online en 2004) y Reino Unido (en 1999). Ambos países venden todo tipo de medicamentos por internet, tanto los que precisan receta como los que no. Precisamente, esta es la primera consideración que hace el Presidente de Cofares: en España los medicamentos que podrán venderse online son los OTC, es decir, los que no precisan prescripción médica. 

González Bosch descarta, además, que esté cercano el día en el que los medicamentos que sí requieren receta médica puedan venderse a través de internet. Considera que la venta online de este tipo de medicamentos no sería deseable puesto que la receta médica es ‘un elemento importantísimo a la hora de garantizar la seguridad del paciente’. 

 Por otro lado, el presidente de Cofares explica que existen dos requisitos básicos para que las farmacias puedan vender medicamentos OTC online. 

  • El primero es una autorización, un permiso que debe solicitarse a la comunidad autónoma en la que se encuentre la farmacia en cuestión. 
  • El segundo es que los medicamentos que se vendan deben tener un logotipo común que deberá estar claramente visible en cada una de las páginas del sitio web relacionadas con la oferta al público de medicamentos. El logotipo se ajustará a lo que determine en la normativa específica de la Unión Europea. 

Por último, para la compra online de medicamentos es necesario tener claro que los medicamentos que se adquieran a través de internet no pueden devolverse. Carlos González Bosch incide en la conservación del producto adquirido por el paciente como motivo para que no pueda devolverse el medicamento en cuestión. ‘Un medicamento que necesite frío para conservarse adecuadamente, pierde su trazabilidad una vez adquirido’, explica. (Ver)


miércoles, 30 de septiembre de 2015

Pharma needs to ensure access to medicines without damaging R&D / Prof. Ralf Boscheck*

Prof. Ralf Boscheck
International intellectual property regulations are doing serious damage to the pharmaceutical industry and, by extension, to the health of people around the world.

The core of the problem: growing global concern about how to ensure affordable access to medicine without damaging the initiatives that sustain pharmaceutical research. Attempts to address the issues have resulted in significant disagreement between developed and emerging economies about just how much protection should be available to companies that develop new drugs.

Members of the World Intellectual Property Organisation, which celebrated its 40th anniversary this year, are trying to resolve their differences on how – and even whether – emerging market countries should move to a framework that offers greater intellectual property (IP) protection, but the results to date are not promising.

'Access to medicine' advocates propose measures based on national income levels; branded drug producers want a time-based transition schedule; others argue that patent protection should be linked with the UN’s Human Development Index, which is a relative scale with frequently-changing outcomes and policy incomes.

The case for strong patent protection

Developed countries, particularly the United States, usually try to commit emerging economies to more stringent intellectual property right rules in exchange for bilateral concessions in other areas of trade. These arrangements typically involve an extension of patent terms and data exclusivity as well as limits to parallel trade and accelerated marketing approval for generic producers.

Strengthening intellectual property rights, they argue, incentivises research on diseases that are specific to developing countries and promotes technology transfer through the localisation of R&D and production investments. This then contributes to improving typically inadequate health service infrastructures.
The 'evergreening' debate
'Evergreening' is a series of techniques used by pharmaceutical firms to continue protecting their drugs after the initial patent expires in order to maximise their return on R&D investments. That is, they prevent or limit the manufacture of generic drugs for longer.
The specific approaches used are numerous, but include 
  • continued differentiation of branding, dosing, formulation or mode of action; 
  • patenting active compounds or co-specialised delivery systems; and
  • seeking to expand a compound’s market through approvals for new indications.

 The 'evergreening' debate
Critics of evergreening strategies argue that this means that patients miss out on the benefits of cheaper generic drugs. However, they also usually neglect the existence of regulatory and market responses that limit the risk of abusive patenting.
For instance, patentability typically requires an invention to be novel, non-obvious and useful in the sense of capable of industrial application. The coloring and scoring of a drug may appear on the surface to be purely aesthetic, but if it can be shown to improve patient compliance, and therefore efficacy, that is novel and not obvious, and must therefore be patentable. In short, properly designed and implemented patent systems already deal with some of the often claimed evergreening concerns. 


Evergreening of patents in pharma field / Novartis en India...

Escalating healthcare expenditures and the need to ensure access to affordable medicine in both emerging and emerged economies are fuelling calls for containing evergreening practices around the world. But such practices are the necessary outcome of a system that responds to market incentives and is already sufficiently controlled by established patentability standards and policies to determine patent term extension. Even reverse payment arrangements may ultimately deliver consumer net benefits. They present a challenge for efficient rule writing and a reminder of the need for better and coordinated policy analysis.(Más)


Access to medicines.

(*) Ralf Boscheck is the Lundin Family professor of economics and business policy at IMD and director of IMD’s MBA program. With more than 20 years of teaching, Boscheck believes in using intensive and direct interaction to develop technical competencies, self-awareness and moral judgment.